Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite
NCT ID: NCT00897247
Last Updated: 2014-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
494 participants
OBSERVATIONAL
2007-01-31
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This laboratory study is looking for biomarkers to detect mesothelioma early in patients exposed to asbestos or vermiculite.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mesothelioma Early Detection by VOCs
NCT04106973
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
NCT04431024
Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107
NCT00898547
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
NCT01950572
Observational Prospective Analysis of Biological Characteristics of Mesothelioma Patients
NCT02300883
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Identify patients with known asbestos exposure at early stages of disease development (i.e., indolent premalignant pleural plaques and fibrosis vs malignant pleural mesothelioma).
* Determine the expression levels of tumor-associated proteins in these patients.
* Analyze samples of serum and pleural effusions obtained from these patients.
* Determine the proteomic profile of samples obtained from these patients.
* Determine the molecular mechanisms associated with the regulation of the extracellular matrix microenvironment proteins (e.g., osteonectin, intelectin, or matrix metalloproteins) involved in disease onset and progression.
OUTLINE: This is a multicenter study.
Patients undergo collection of body cavity fluid, including pleural effusion, and blood. Specimens, including fresh frozen malignant pleural mesothelioma tumor tissue, if available, are analyzed for proteomic profile, gene expression profile, and tumor-associated protein expression levels.
PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
microarray analysis
protein expression analysis
proteomic profiling
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Exposure to vermiculite or asbestos insulation
* Symptomatic or nonsymptomatic exposure-related disease
* Seen at a clinic in Libby, Montana (CARD Clinic) or Michigan (COEM)
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
25 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Barbara Ann Karmanos Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anil Wali, PhD
Role: STUDY_CHAIR
Barbara Ann Karmanos Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WSU-2006-057
Identifier Type: -
Identifier Source: secondary_id
WSU-HIC-094806MP2F
Identifier Type: -
Identifier Source: secondary_id
CDR0000518348
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.